Medtronic Announces European Launch of World s First Infusion Set with Wear up to Seven Days to Help Reduce Burden for People with Diabetes
News provided by
Share this article
Share this article
DUBLIN, April 14, 2021 /PRNewswire/ Medtronic plc (NYSE: MDT), the global leader in medical technology, today introduced in select European countries the Medtronic Extended infusion set the first and only infusion set that can be worn for up to 7 days. An infusion set is tubing that delivers insulin from the pump to the body and typically requires a set change every few days.
The innovative design of the Medtronic Extended Infusion Set leverages advanced materials that help reduce insulin preservative loss and maintains insulin flow and stability. The new tubing connector improves physical and chemical stability of insulin, reliability of infusion site performance, and reduces the risk of infusion set occlusion. The adhesive patch has an adhesive layer that extends wear time and du
Medtronic Announces European Launch of World s First Infusion Set with Wear up to Seven Days to Help Reduce Burden for People with Diabetes
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Medtronic Announces European Launch of World s First Infusion Set with Wear up to Seven Days to Help Reduce Burden for People with Diabetes
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
Sean Salmon Named EVP & President Cardiovascular Portfolio; Continues as EVP & President Diabetes Operating Unit
News provided by
Share this article
Share this article
DUBLIN, Dec. 14, 2020 /PRNewswire/ Medtronic plc (NYSE:MDT) announced today that Sean Salmon, Executive Vice President and President, Diabetes Operating Unit has been named Executive Vice President and President, Cardiovascular Portfolio effective January 1. Salmon will also continue to lead the Diabetes Operating Unit and continue to serve on the company s Executive Committee. He succeeds Mike Coyle, who will leave Medtronic effective December 31 to accept a CEO role of a publicly traded company. We owe Mike a debt of gratitude for his significant contributions to Medtronic, said Geoff Martha, Medtronic Chairman and Chief Executive Officer. He s played a vital role in our Cardiovascular portfolio, including overseeing the development and launches of numerous disruptive and life-saving technologies. On behal